Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety

Phio Pharmaceuticals Corp.

Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.
G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.
PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.
ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.